Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03614975 · ClinicalTrials.gov registry record · Phase 4
Immunologic Response to Influenza Vaccination in Children and Adolescents
A Phase 4 study, sponsored by Richard Zimmerman MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 166
- Enrollment target
NCT03614975 is a Phase 4 study that has completed, run by Richard Zimmerman MD. The registered enrollment target is 166 participants.
The verdict
NCT03614975, a Phase 4 study, has completed, sponsored by Richard Zimmerman MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 166 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-20 years of age. This is a randomized controlled trial (RCT), that will assess immune response in 120 participants (60 per vaccine arm) pre- and post-vaccination to Flucelvax (egg-free inactivated flu shot) and Fluzone (egg-based inactivated flu shot).
Interventions
- BIOLOGICAL Flucelvax inactivated influenza vaccine
- BIOLOGICAL Fluzone inactivated influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2018-12-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03614975
The ClinicalTrials.gov registry entry for NCT03614975 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Richard Zimmerman MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flucelvax inactivated influenza vaccine is the first listed.
NCT03614975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03614975 about?
NCT03614975 is a clinical study titled "Immunologic Response to Influenza Vaccination in Children and Adolescents". The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-20 years of age. This is a randomized controlled trial (RCT), that will assess immune response in 120 participants (60 per vaccine arm) pre- and post-vaccin...
What is the current status of trial NCT03614975?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 166 participants. The study started on 2018-09-13. Estimated completion is 2018-12-13.
What interventions are being tested in trial NCT03614975?
The interventions under investigation include: Flucelvax inactivated influenza vaccine (BIOLOGICAL), Fluzone inactivated influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03614975?
This trial is sponsored by Richard Zimmerman MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.